SINO BIOPHARMACEUTICAL LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.81 HKD | -1.06% |
|
-1.06% | -19.02% |
| Sales 2024 * | 29.1B 4.02B 31.4B 334B | Sales 2025 * | 32.3B 4.46B 34.86B 371B | Capitalization | 48.23B 6.66B 52.05B 553B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.73B 376M 2.94B 31.28B | Net income 2025 * | 3.11B 429M 3.36B 35.66B | EV / Sales 2024 * | 1.51 x |
| Net cash position 2024 * | 4.36B 602M 4.71B 50.06B | Net cash position 2025 * | 7.41B 1.02B 8B 85.02B | EV / Sales 2025 * | 1.26 x |
| P/E ratio 2024 * |
17.8
x | P/E ratio 2025 * |
15.6
x | Employees | 25,806 |
| Yield 2024 * |
2.06% | Yield 2025 * |
2.4% | Free-Float | 50.56% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -1.06% | ||
| 1 week | -1.06% | ||
| Current month | -1.06% | ||
| 1 month | -2.09% | ||
| 3 months | -10.79% | ||
| 6 months | -21.07% | ||
| Current year | -19.02% |
1 week
2.78
2.93
1 month
2.773.18
Current year
2.293.49
1 year
2.293.90
3 years
2.298.78
5 years
2.2911.24
10 years
1.7611.24
| Managers | Title | Age | Since |
|---|---|---|---|
S Y Tse
CEO | Chief Executive Officer | 29 | 23/19/23 |
Ping Tse
FOU | Founder | 72 | 02/00/02 |
Chun Ling Li
DFI | Director of Finance/CFO | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ping Tse
FOU | Founder | 72 | 02/00/02 |
| Director/Board Member | 60 | 01/05/01 | |
Hsin Tse
BRD | Director/Board Member | 54 | 01/95/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.40% | 2 M€ | -18.79% | - | |
| 2.02% | 4 M€ | -27.92% | ||
| 0.82% | 3 M€ | +0.10% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 2.81 | -1.06% | 32 097 766 |
| 31/24/31 | 2.84 | +1.43% | 134,336,900 |
| 30/24/30 | 2.8 | 0.00% | 35,233,830 |
| 29/24/29 | 2.8 | -2.78% | 29,362,370 |
| 28/24/28 | 2.88 | +1.41% | 49,565,140 |
Delayed Quote Hong Kong S.E., June 03, 2024 at 08:49 am IST
More quotes
Sino Biopharmaceutical Limited specialises in the development, manufacture and marketing of biopharmaceutical products primarily for the treatment of cancer, ophthalmia, hepatitis, orthopedic diseases and respiratory disorders. Net sales break down by category of products as follows:
- chemical medicine products and biopharmaceutical drugs (97.6%);
- other (2.4%).
Sector
Pharmaceuticals
Calendar
11/06/2024
- Final dividend
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
2.63
CNY
Average target price
4.256
CNY
Spread / Average Target
+61.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.02% | 6.66B | |
| +40.73% | 739B | |
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B |
- Stock Market
- Equities
- 1177 Stock
